Literature DB >> 17030267

Epidemiology of adenocarcinoma of the esophagogastric junction.

Scott Keeney1, Thomas L Bauer.   

Abstract

The incidence of adenocarcinoma of the esophagogastric junction has increased rapidly in the later half of the twentieth century in the United States and most western countries. Although squamous cell carcinoma of the esophagus used to predominate, adenocarcinoma of the distal esophagus and esophagogastric junction now accounts for more than half of new diagnoses in western countries. There also has been a shift from the development of distal gastric cancers to ones in a more proximal location. These recent epidemiologic shifts have led to controversy regarding the etiology and treatment of adenocarcinoma of the esophagogastric junction. Uncertainty still exists with regards to nomenclature and classification, risk factors, treatment, and screening and surveillance of esophagogastric adenocarcinoma. This article examines the epidemiology and etiologies of adenocarcinoma of the esophagogastric junction.

Entities:  

Mesh:

Year:  2006        PMID: 17030267     DOI: 10.1016/j.soc.2006.07.014

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  11 in total

1.  Evidence based radiation therapy for locally advanced resectable and unresectable gastric cancer.

Authors:  Georgios V Koukourakis
Journal:  World J Gastrointest Oncol       Date:  2011-09-15

2.  Expression of stem cell markers nanog and PSCA in gastric cancer and its significance.

Authors:  Xuanzhong Zhao; Feng Wang; Mingxing Hou
Journal:  Oncol Lett       Date:  2015-11-06       Impact factor: 2.967

Review 3.  Carcinoma of the gastroesophageal junction in Chinese patients.

Authors:  Qin Huang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

4.  Psychiatric illness delays diagnosis of esophageal cancer.

Authors:  R W O'Rourke; B S Diggs; D H Spight; J Robinson; K A Elder; J Andrus; C R Thomas; J G Hunter; B A Jobe
Journal:  Dis Esophagus       Date:  2008       Impact factor: 3.429

5.  The length of proximal margin does not influence the prognosis of Siewert type II/III adenocarcinoma of esophagogastric junction after transhiatal curative gastrectomy.

Authors:  Fan Feng; Yangzi Tian; Guanghui Xu; Shushang Liu; Zhen Liu; Gaozan Zheng; Man Guo; Xiao Lian; Daiming Fan; Hongwei Zhang
Journal:  Springerplus       Date:  2016-05-11

6.  Short-term postoperative complications and prognostic factors in patients with adenocarcinoma of the esophagogastric junction.

Authors:  Hui Zhang; WeiJian Zhang; DeFeng Peng; JinHai Zhu
Journal:  Thorac Cancer       Date:  2018-06-21       Impact factor: 3.500

7.  Optimal Extent of Transhiatal Gastrectomy and Lymphadenectomy for the Stomach-Predominant Adenocarcinoma of Esophagogastric Junction: Retrospective Single-Institution Study in China.

Authors:  Baoyu Zhao; Zhenzhan Zhang; Debin Mo; Yiming Lu; Yanfeng Hu; Jiang Yu; Hao Liu; Guoxin Li
Journal:  Front Oncol       Date:  2019-01-21       Impact factor: 6.244

8.  Prognostic Importance of the Preoperative Naples Prognostic Score for Patients With Adenocarcinoma of the Esophagogastric Junction.

Authors:  Jianping Xiong; Yaqin Wang; Wenzhe Kang; Fuhai Ma; Hao Liu; Shuai Ma; Yang Li; Peng Jin; Haitao Hu; Yantao Tian
Journal:  Front Oncol       Date:  2020-12-16       Impact factor: 6.244

9.  Analysis of N6-Methyladenosine Methylome in Adenocarcinoma of Esophagogastric Junction.

Authors:  Jia-Bin Huang; Bin-Bin Hu; Rong He; Lian He; Chen Zou; Chang-Feng Man; Yu Fan
Journal:  Front Genet       Date:  2022-01-24       Impact factor: 4.599

10.  Model established based on blood markers predicts overall survival in patients after radical resection of types II and III adenocarcinoma of the esophagogastric junction.

Authors:  Zhi-Jian Wei; Ya-Ting Qiao; Bai-Chuan Zhou; Abigail N Rankine; Li-Xiang Zhang; Ye-Zhou Su; A-Man Xu; Wen-Xiu Han; Pan-Quan Luo
Journal:  World J Gastrointest Surg       Date:  2022-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.